ArticleDiagnostics (Basel, Switzerland)2024
Explainable AI for Interpretation of Ovarian Tumor Classification Using Enhanced ResNet50.
Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of ovarian cancer using convolutional neural network: a systematic review and meta-analysis.BMC medical informatics and decision making · 2026Pooled it
- Evaluating Performance of a Deep Learning-based Artificial Intelligence Model for Ovarian Tumor Classification Using a Multicenter CT Dataset.Radiology. Imaging cancer · 2026Article
- Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention.Journal of ovarian research · 2026Review
- Multiple perception contrastive learning for automated ovarian tumor classification in CT images.Abdominal radiology (New York) · 2025Article
- Advanced dynamic ensemble framework with explainability driven insights for precision brain tumor classification across datasets.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning architectures like ResNet and Inception have produced accurate predictions for classifying benign and malignant tumors in the healthcare domain. This enables healthcare institutions to make data-driven decisions and potentially enable early detection of malignancy by employing computer-vision-based deep learning algorithms. These CNN algorithms, in addition to requiring huge amounts of data, can identify higher- and lower-level features that are significant while classifying tumors into benign or malignant. However, the existing literature is limited in terms of the explainability of the resultant classification, and identifying the exact features that are of importance, which is essential in the decision-making process for healthcare practitioners. Thus, the motivation of this work is to implement a custom classifier on the ovarian tumor dataset, which exhibits high classification performance and subsequently interpret the classification results qualitatively, using various Explainable AI methods, to identify which pixels or regions of interest are given highest importance by the model for classification. The dataset comprises CT scanned images of ovarian tumors taken from to the axial, saggital and coronal planes. State-of-the-art architectures, including a modified ResNet50 derived from the standard pre-trained ResNet50, are implemented in the paper. When compared to the existing state-of-the-art techniques, the proposed modified ResNet50 exhibited a classification accuracy of 97.5 % on the test dataset without increasing the the complexity of the architecture. The results then were carried for interpretation using several explainable AI techniques. The results show that the shape and localized nature of the tumors play important roles for qualitatively determining the ability of the tumor to metastasize and thereafter to be classified as benign or malignant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.